Myriad Genetics (MYGN) Q2 2026 earnings — TrendMatrix coverage
MISS · WIDER LOSS-332.7% vs estimateEPS -$0.25 vs -$0.06 estVerdict Sell → Hold
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
Key numbers
- Reported EPS
- -$0.25
- Estimate
- -$0.06
- Surprise
- -332.7%
- Score at report (before → after)
- 4.7 → 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Report record · Q2 2026
How the report landed
Myriad Genetics (MYGN) reported a wider loss than forecast — diluted EPS of -$0.25 against the -$0.06 estimate (a 332.7% shortfall). TrendMatrix's engine moved from Sell (4.7/10) to Hold at 5.3/10 after the report — the engine's score rose despite the miss.